Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNexin Phase 1b in Dry Eye Disease
NCT05031806Phase 1Completed
- Sponsor
- Xequel Bio
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aCT1 in dry eye disease (DED) (4 arms), sponsored by Xequel Bio. Primary endpoints: Evaluation of the safety of iNexin at 24 days and Evaluation of the tolerability of iNexin at 24 days. Started Sep 2021; status: completed.
02
Drugs
aCT1
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05031806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05031806.